Trial site
breast cancer institute of Fudan University Cancer Hospital
Shanghai, Shanghai Municipality 200032, ChinaNot linked to an institution yet
- 11running trials
- 1closed trial
The trials here
What the 12 trials at this site are about, from their registry records.
- Phase
- Phase 26 trials
- Phase 36 trials
- Status
- Recruiting8 trials
- Active, not recruiting2 trials
- Completed1 trial
- Not yet recruiting1 trial
- Lead sponsor
- Fudan University11 trials
- Zhimin Shao1 trial
Running trials
Not yet recruiting
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
NCT06731153· Phase 2· Fudan University· Source
Recruiting
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT06649331· Phase 2· Fudan University· Source
Contact: Zhimin Shao, M.D
Active, not recruiting
PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT06612814· Phase 3· Zhimin Shao· Source
Recruiting
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
NCT05999149· Phase 3· Fudan University· Source
Contact: Zhi-Ming Shao, MD
Recruiting
Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)
NCT05909332· Phase 3· Fudan University· Source
Contact: Zhi-Ming Shao, MD
Recruiting
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
NCT05862064· Phase 3· Fudan University· Source
Contact: Zhi-Ming Shao, MD
Recruiting
Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer
NCT05806060· Phase 3· Fudan University· Source
Contact: Zhi-Ming Shao, MD
Recruiting
Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.
NCT05760378· Phase 3· Fudan University· Source
Contact: Zhi-Ming Shao, MD
Active, not recruiting
Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer
NCT05759572· Phase 2· Fudan University· Source
Recruiting
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
NCT05759546· Phase 2· Fudan University· Source
Contact: Zhi-Ming Shao, MD
Recruiting
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05594095· Phase 2· Fudan University· Source
Contact: Zhi-Ming Shao, MD
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error